Abciximab reduced death, MI, and urgent target vessel revascularization in non-ST-segment elevation acute coronary syndromes: COMMENTARY

Hudson, Michael P.
July 2006
ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p8
Academic Journal
The article presents the author's views on the optimal therapy for acute coronary syndrome. In the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial by researcher A. Kastrati and colleagues, clinical benefit were exhibited by abciximab over placebo after clopidogrel therapy decreased a composite endpoint of death. The effect of glycoprotein IIb/IIIa treatment was increased and found to be significant only in the higher-risk, troponin-positive patients.


Related Articles

  • Benefits and limitations of current antiplatelet therapies. Nappi, Jean // American Journal of Health-System Pharmacy;7/1/2008, Vol. 65 Issue 13, pS5 

    Purpose. The benefits and limitations of current antiplatelet therapies in the management of patients experiencing acute coronary syndrome (ACS) are reviewed. Summary. Antiplatelet agents, including aspirin, thienopyridines, and platelet glycoprotein (GP) IIb/IIIa receptor inhibitors, have...

  • Effect of PUFAs on chronic heart failure.  // Clinical Cardiology Alert;Dec2008 Clinical Briefs in Primary, Vol. 13 Issue 12, p24 

    The article focuses on a study which examines the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with chronic heart failure (CHF). It states that this study was participated by CHF patients who were enrolled in a randomized placebo-controlled trial of 1 gram per day PUFAs. It...

  • Antiarrhythmic will be withdrawn from market.  // Geriatrics;Oct1991, Vol. 46 Issue 10, p23 

    The article reports that the antiarrhythmic medication encainide HCL (Enkaid) will be effective from the market effective December 16. Bristol Laboratories said the decision is based upon continuing uncertainty regarding the implications of the Cardiac Arrhythmia Suppression Trial (CAST) as well...

  • Some ACCLAIM for immune modulation in chronic heart failure. Lindsay, Alistair // Heart;May2008, Vol. 94 Issue 5, p676 

    The article discusses the study of the effect of the immunomodulation on the morbidity and mortality of 2426 patients with class II-IV heart failure. The study was done through a placebo-controlled trial called Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy...

  • Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction. Antoniucci, David // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jul2005, Vol. 3 Issue 3, p173 

    Limitations in study designs and adoption of rigid criteria for randomization in clinical trials on acute myocardial infarction (AMI) may result in the enrolment of artificial populations, and subsequent trial results may be misleading in many ways rendering problematic the generalization of the...

  • Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial†. Gheorghiade, Mihai; Patel, Kanan; Filippatos, Gerasimos; Anker, Stefan D.; van Veldhuisen, Dirk J.; Cleland, John G.F.; Metra, Marco; Aban, Inmaculada B.; Greene, Stephen J.; Adams, Kirkwood F.; McMurray, John J.V.; Ahmed, Ali // European Journal of Heart Failure;May2013, Vol. 15 Issue 5, p551 

    Aims In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or hospitalization due to heart failure (HF) in several pre-specified high-risk subgroups of HF patients, but data on protocol-specified 2-year outcomes were not presented. In the current study, we examined the...

  • MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Genth-Zotz, Sabine; Zotz, Rainer J.; Sigmund, Martin; Hanrath, Peter; Hartmann, Dagmar; Böhm, Michael; Waagstein, Finn; Treese, Norbert; Meyer, Jürgen; Darius, Harald // European Journal of Heart Failure;Jun2000, Vol. 2 Issue 2, p175 

    Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with...

  • Antioxidants & Estrogen Strike Out.  // Nutrition Action Health Letter;Jan/Feb2003, Vol. 30 Issue 1, p12 

    Reports that postmenopausal women with heart disease who were given estrogen or high doses of antioxidants had a higher risk of dying than those who took a placebo, according to a study published in a 2002 issue of the 'Journal of American Medical Association.'

  • Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP.  // Evidence Based Medicine;Feb2005, Vol. 10 Issue 1, p9 

    The article focuses on patients with severe chronic heart failure, in which carvedicol reduced the risk of all cause mortality and combined mortality and general and cause specific hospital admission regardless of pretreatment systolic blood pressure. More patients in the carvedilol group than...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics